The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Boston… Read More
Philip Greenberg has been trying to stop cancer for decades. With Affini-T Therapeutics, the Fred Hutchinson Cancer Research Center investigator may finally have his chance. The company announced $175 million… Read More
Pharmaceutical giant Bristol Myers Squibb has been quietly growing in the Seattle area. Since acquiring Celgene and its Seattle operations two years ago, BMS now has more than 1,240 employees… Read More
Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 million. Immusoft’s… Read More
At home and at work, Justine Dell’Aringa is up for a challenge. The scientific associate director of Translational Research for Bristol Myers Squibb’s Immuno-Oncology and Cell Therapy Thematic Research Center… Read More
Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2), announced $3.5 million in seed funding. The company combines laboratory research with machine… Read More
Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene therapy and gene editing. Backed by ARCH Venture Partners, Flagship… Read More